Results 51 to 60 of about 20,680 (257)
Pityriasis following COVID-19 vaccinations: a systematic review
Dermatology Reports, 2023 In the wake of a global COVID-19 pandemic, where innovations in vaccination technology and the speed of development and distribution have been unprecedented, a wide variety of post-vaccination cutaneous reactions have surfaced.
Laura Duzett +4 more
doaj +1 more source
Dermoscopic features of pityriasis rosea
BMJ Case Reports, 2023 © BMJ Publishing Group Limited 2023. No commercial reuse. See rights and permissions. Published by BMJ. DESCRIPTION A woman in her 20s presented with an erythematous, itchy, scaly rash on her trunk and extremities for 3 weeks duration.
Shivani Vasisht, N. Kansal
semanticscholar +1 more source
Pityriasis Rosea Variant: Persistent Pityriasis Rosea in a 78-Year-Old Female Patient
Annals of Internal Medicine: Clinical Cases, 2023 Pityriasis rosea (PR) is a papulosquamous dermatosis seen most commonly in children and young adults. Variants of PR occur in 1 in 5 cases and can significantly impact a patient's quality of life.
Evelyn Fagan +3 more
doaj +1 more source
Pityriasis Rosea Recurrence is Much Higher than Previously Known: A Prospective Study
Acta Dermato-Venereologica, 2019 Pityriasis rosea is a common acute exanthema of unknown aetiology, which causes severe anxiety. In this study, the demographic data of pityriasis rosea patients, who presented to our clinic between 2013 and 2017, were prospectively recorded. The patients
Mavişe Yüksel
doaj +1 more source
Six cases of pityriasis rosea following SARS‐CoV‐2 vaccination with BNT162b2
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2022 The development of vaccines against SARS-CoV-2 has been extremely quick [1–6], and currently the Moderna mRNA1273, Pfizer/BioNTech BNT162b2 mRNA, and the AstraZeneca/University of Oxford ChAdOx1-nCoV-19 chimpanzee adenovirus (ChAd) vector vaccines have ...
Y. Ramot +5 more
semanticscholar +1 more source
Cutaneous reactions after COVID-19 vaccination in Turkey: A multicenter study [PDF]
, 2022 Objectives In this study covering all of Turkey, we aimed to define cutaneous and systemic adverse reactions in our patient population after COVID-19 vaccination with the Sinovac/CoronaVac (inactivated SARS-CoV-2) and Pfizer/BioNTech (BNT162b2) vaccines.
Aktaş, Nurhan Döner +6 more
core +1 more source
An expert system for the differential diagnosis of erythemato-squamous diseases [PDF]
, 2000 Cataloged from PDF version of article.This paper presents an expert system for differential diagnosis of erythemato-squamous diseases incorporating decisions made by three classification algorithms: nearest neighbor classifier, naive Bayesian classifier ...
Emeksiz, N., Guvenir, H. A.
core +1 more source
Atypical pityriasis rosea in a young Colombian woman. Case report
Case Reports, 2021 Introduction: Pityriasis rosea is an acute and self-limited exanthem first described by Gilbert in 1860. Its treatment is symptomatic, and although there is no conclusive evidence, it has been associated with the reactivation of the human herpesviruses ...
Julián Felipe Porras-Villamil +3 more
doaj +1 more source
Coronavirus disease 2019 and pityriasis rosea: A review of the immunological connection
Journal of dermatology (Print), 2022 Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is characterized by the activation of a cytokine storm derived from an excess release of cytokine (interleukin [IL]‐6, interferon [IFN] I, C‐X‐C motif chemokine ligand [CXCL]10, tumor necrosis ...
F. Borgia +5 more
semanticscholar +1 more source
Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec™) [PDF]
, 2011 Imatinib mesylate (Gleevec™, STI571), a selective inhibitor of BCR-ABL, c-Kit, and platelet-derived factor receptor, has been used to treat chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors.
Cho, Ah Young +5 more
core +2 more sources